Review

Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers

Chunhong Qin1,2,#, Yan Lu2,3,#, Huimin Zhang2,#, Zhe Zhang2,4, Wei Xu5, Shuxin Wen6,7, Wei Gao7,2,5, Yongyan Wu7,1,2,5,6

1. Department of Biochemistry & Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan 030001, Shanxi, China.
2. Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, Department of Otolaryngology Head & Neck Surgery, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, China.
3. Department of Otolaryngology Head & Neck Surgery, The First Hospital, Jinzhou Medical University, Jinzhou 121001, Liaoning, China.
4. Shaxi Eye Hospital, Taiyuan 030002, Shanxi, China.
5. Department of Otolaryngology-Head and Neck Surgery, Shandong Provinical ENT Hospital, Cheeoo College of Medicine, Shandong University, Jinan 250022, Shandong, China.
6. Department of Otolaryngology Head & Neck Surgery, Shanxi Bethune Hospital, Taiyuan 030032, Shanxi, China.
7. General Hospital, Clinical Medical Academy, Shenzhen University, Shenzhen 518055, Guangdong, China.

#These authors contributed equally to this work.

Corresponding authors: Yongyan Wu, Ph.D., Professor, E-mail: wuyongyan@szu.edu.cn, ORCID: 0000-0003-1669-3860; Wei Gao, M.D., Professor, Email: wei.gao@szu.edu.cn, ORCID: 0000-0001-7836-2851; Shuxin Wen, M.D., Professor, Email: wsxsx@sxent.org, ORCID: 0000-0002-8377-2481.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

See http://ivyspring.com/terms for full terms and conditions.

Received: 2021.09.01; Accepted: 2022.03.17; Published: 2022.04.04

Abstract

Head and neck cancers (HNC) include malignant tumors that grow in and around the mouth, larynx, throat, sinuses, nose, and salivary glands. Accumulating evidence in malignancies suggests the aberrant expressions of the estrogen receptor (ER) and the androgen receptor (AR) in HNC, such as in laryngeal cancer and cancer of the salivary gland. Moreover, the signaling pathways involving these receptors that mediate tumorigenesis, proliferation, apoptosis, migration, and invasion have been elucidated. This review summarizes the roles of ER and AR with the putative signaling pathways involved in HNC. We also discuss the potential application of ER- and AR-related therapies in HNC. However, most of the mechanisms underlying AR and ER involvement in the development of HNC remain elusive and warrant further studies. A comprehensive understanding of the functional roles and mechanisms of action of AR and ER in HNC will facilitate the development of better therapeutic strategies for this disease. Overall, studies on AR and ER provide a promising potential for the diagnosis and treatment of HNC in the future.

Key words: Androgen receptor; Estrogen receptor; Head and neck cancer; Molecular target; Biomarker; Cancer treatment

Background

Head and neck cancers (HNC) are one of the most lethal and predominant tumors, worldwide, accounting for 5.7% of the total global mortality due to cancers [1-3]. Its potential epidemiological trend shows an uneven regional distribution of disease burden. For instance, the Swedish Head and Neck Cancer Register (SweHNCR) report suggests that among the 9733 patients diagnosed with HNC between 2008 - 2015, approximately 10% died within six months of diagnosis [4]. In 2019, an estimated 66,630 new cases of HNC were diagnosed and 14,620 individuals died due to this disease in the United States [5]. Based on the epidemiological research data from 2008 to 2012, in Shanxi Province, China, the average annual incidence rate of laryngeal cancer was 0.70/105 [6]. Remarkably, the essential risk factors of HNC include tobacco and alcohol use, and infection by the human papillomavirus (HPV) [7, 8]. Additionally, other factors have been identified by the epidemiological studies of HNC, including genetics, toxic exposure, diet, and environmental conditions [3, 9, 10].

Radiotherapy and chemotherapy are the most predominant adjuvant treatments for HNC [11].
Radiotherapy can facilitate clinical outcomes to a certain extent but also is accompanied by some side effects of radiation, such as dry mouth symptoms and difficulties in chewing/swallowing [12, 13]. Recently, the use of cetuximab and taxane has been on the rise [14], and the combined induction using gemcitabine and cisplatin suggests a new possibility for improving the recurrence-free survival rate [15]. Despite these benefits, the disadvantages of chemoresistance, toxic side effects, and acute adverse events [16] have not been addressed, thus warranting further studies. In the past few years, due to the low toxicity of combination chemotherapy, that is, the integration of chemotherapy and combined androgen blockade (CAB) using the androgen receptor (AR) antagonist, the research attention for its clinical applicability has gained traction [17]. For example, patients with advanced AR-positive salivary duct carcinoma exhibit increased overall survival after undergoing androgen-deprivation therapy (ADT) [18]. Correspondingly, in breast cancer, the estrogen receptor-α (ERα) serves as a molecular target for endocrine therapy and binds estrogen to mediate metastasis [19]. Taken together, these studies indicate that AR and ER have promising roles in the management of cancers including HNC.

In this review, we have summarized the current knowledge on the functional roles of ER and AR in HNC (Fig. 1) and discussed their putative applications in treatment and diagnosis. Moreover, as anti-androgen and anti-estrogen therapies continue to be regarded as potential therapeutic strategies, targeting ER and AR signaling pathways may prove useful for the treatment of patients with HNC.

**ER-mediated signaling pathways**

Estrogen receptors (ERs) are typical members belonging to the superfamily of nuclear receptors that include receptors involved in the action of steroid hormones, thyroid hormones, vitamin D, and several orphan receptors [20]. These receptors are primarily classified into two categories, namely the classical nuclear receptors, comprising ERα and ERβ, localized in the nucleus and mediating the effects of estrogen and the membranous receptors, including the membranous components of the classical nuclear receptor and the G protein-coupled estrogen receptor 1 (GPER1) [21, 22].

Estrogen either enters the cell or is synthesized within. It binds with the nuclear ER, thereby forming an ER homodimer or heterodimer [21]. The activated ER interacts with the DNA enhancer response element (ERE) resulting in the ER-ERE complex, which further facilitates the formation of a transcription initiation complex that induces transcription, and thus, the ER exerts its functions [23]. Estrogen can produce biological effects through the rapid activation of intracellular secondary signaling systems through the ER membrane [24]. These effects include (1) the rapid activation of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway, (2) stimulation of adenylate cyclase (cAMP), thereby promoting the activity of cAMP-regulated gene transcription, and (3) activation of protein kinase C (PKC) increasing in endogenous Ca2+ levels [23-28]. Additionally, there are other ER-mediated pathways, including the c-Jun N-terminal kinase (JNK) pathway, which induces apoptosis, and the phosphatidylinositol 3 kinase (PI3K) pathway that inhibits apoptosis [22, 29, 30]. Finally, the classical estrogen signaling is through the membrane-associated 17β-estradiol (E2)-ER binding, which triggers multiple rapid signal transduction cascades [24, 31] (Fig. 2).

**AR-mediated signaling pathways**

The AR is similar to the ER in that they belong to the superfamily of nuclear receptors [32]. The length of the AR gene, located on xq11-12, is greater than 90 kb. It has eight exons, wherein exon 1 is at the amino-terminus and is responsible for stimulating the gene transcription [33, 34]. Thus, AR acts as a transcription factor and consequently translocates to
the nucleus following the binding of the active androgen dihydrotestosterone (DHT) [33] (Fig. 1). The AR contains four functional regions as follows: the N-terminal domain, DNA-binding domain (DBD), ligand-binding domain, and a hinge [34]. A typical signaling pathway involving AR consists of different stages [35]. First, the AR binds to androgen (DHT) causing a conformational change, and thus, the AR separates from the heat shock proteins and enters the nucleus through the nuclear pore [34]. In the nucleus, AR undergoes phosphorylation and dimerization and can recognize the androgen response elements (AREs) on target genes, thereby binds to them and causing chromatin remodeling in an effect to open up the regulatory regions of promoters, eventually recruiting co-activators for the formation of transcriptional complexes, ultimately leading to transcription of the target gene [33, 35]. Forkhead box protein A1 (FOXA1) is a transcription factor of the AR target gene, which regulates its transcription as well as facilitates the interactions of AR with the chromatin [36]. The contribution of AR and FOXA1 to the process of tumorigenesis [37] is illustrated in Fig. 4. Moreover, studies on salivary duct carcinoma show that treatment with DHT increases cell proliferation, migration, and invasion, while the AR inhibitor, fluorouracil, blocks the effects of DHT, suggesting that the androgen-AR signaling axis exerts effects on cellular proliferation, migration, and invasiveness [38].

**Functional roles of ER in the biological behavior of HNC**

Recent studies show that the expression of ERα in laryngeal squamous cell carcinoma (LSCC) is higher relative to the corresponding normal tissues [39]. A similar finding has been reported in malignant minor salivary gland tumors of the sinonasal tract, the majority of which are ER-positive [40]. Likewise, the expression of ERβ is higher in head and neck squamous cell carcinoma (HNSCC) as compared to the normal epithelium [41]. Besides, numerous reports confirm that ER immunoreactivity is present in approximately 50% - 80% of the cases in some HNC types [42-46]. Taken together, these findings demonstrate that ERs are highly expressed in most HNC and are closely associated with its development. The roles and underlying mechanisms of action of ER in HNC progression are listed in Table 1.

---

**Figure 2. Multiple signaling pathways of nuclear ER and membrane ER.** Membrane-associated E2-ER signaling pathway. (1) E2-ER activates ERK/MAPK signaling pathway; (2) The activation of PKC increases endogenous levels of Ca2+, which can induce tumorigenesis and metastasis; (3) E2-ER activates JNK pathway and eventually promotes apoptosis; (4) E2-ER involved in the PI3K/AKT pathway suppresses apoptosis; (5) E2-ER activates Camp; E2-ER signaling pathway in the nucleus. Phosphorylation of ER combined with E2 mediates the formation of ER-ERE complex, leading to transcription. ER: estrogen receptor; ERK: extracellular signal-regulated kinase; MAPK: mitogen-activated protein kinase; PKC: protein kinase C; IP3: inositol triphosphate; IP3R: inositol triphosphate receptor; cAMP: activation of adenylyl cyclase; ERE: estrogen response element.
involved in cellular proliferation, anti-apoptosis, and metastasis in 36 activates PKC through E 2 that mediates the α the metastatic factor, Snail, and downregulates E-cadherin (CDH1); ER apoptosis; E 2 activation of ER

Figure 3. PKC-mediated ER

Abbreviations: NA, not available; EGFR: growth factor receptor; ERK: extracellular signal-related kinase; Ref: reference.

Table 1. The estrogen receptor (ER) expression, functions, and mechanisms in head and neck cancers (HNC)

| Receptor | HNC Type               | Expression | Prognosis    | Function                                       | Mechanism                     | Ref. |
|----------|------------------------|------------|--------------|-----------------------------------------------|-------------------------------|------|
| ER       | Laryngeal cancer       | Upregulation | Unfavorable | NA                                            | NA                            | [78] |
| ERβ      | Oropharyngeal cancer   | Upregulation | Favorable   | NA                                            | NA                            | [79] |
| ERα      | Laryngeal cancer       | Upregulation | Unfavorable | NA                                            | NA                            | [39] |
| ERα      | HPV-positive oropharyngeal cancer | Upregulation | Favorable | NA                                            | NA                            | [80] |
| ER       | Laryngeal cancer       | Upregulation | NA          | Promote proliferation and inhibit apoptosis   | NA                            | [50] |
| ERα      | Papillary thyroid cancer (PTC) | Upregulation | NA          | Promote growth of PTC and inhibit apoptosis  | Activate ERK1/2 and autophagy | [47] |
| ERα36    | Laryngeal cancer       | Upregulation | NA          | Inhibit apoptosis and increase aggression     | Activate PKC and phospholipase D | [31] |
| ERβ      | Laryngeal cancer       | Upregulation | Unfavorable | Increase invasion                             | NA                            | [102]|
| ERβ      | Tongue cancer          | Upregulation | NA          | Inhibit apoptosis                              | NA                            | [41] |
| ERβ      | Tongue cancer          | Upregulation | NA          | Inhibit apoptosis and increase aggression     | NA                            | [48] |
| ERβ1     | Papillary thyroid cancer | Upregulation | NA          | Inhibit proliferation                          | NA                            | [52] |
| ERa      | Papillary thyroid cancer | Upregulation | NA          | Promote growth and progression                | NA                            | [52] |
| ER       | Thyroid cancer         | Upregulation | NA          | Promote proliferation                         | Non-genomic pathways          | [101]|
| ER       | Thyroid carcinoma      | Upregulation | NA          | Promote growth of tumor cells                 | Genomic and non-genomic pathways | [53] |
| ER       | Salivary gland cancer  | Upregulation | Unfavorable | NA                                            | NA                            | [55] |
| ERα66    | Laryngeal cancer       | Downregulation | Unfavorable | Increase aggression                            | NA                            | [57] |
| ERβ      | Laryngeal cancer       | Upregulation | NA          | Inhibit aggression                             | Uregulate E-cadherin, activate β-catenin | [58] |

Inhibition of autophagy promotes apoptosis [47]. Moreover, Shatalova et al. demonstrate high levels of ERβ expression in premalignant head and neck lesion cells MSK-Leuk1. Notably, exposure to E2 results in lower cellular apoptosis, and this estrogen-dependent apoptosis can be restored through supplementation with the anti-estrogen drug. However, the association of exposure to E2 with the inhibition of apoptosis and ERβ remains enigmatic and needs further evaluation [41]. Although a group of researchers has provided considerable evidence suggesting that the activity of E2 is associated with its receptor ER, resulting in the enhanced proliferation and conferring anti-apoptotic potential to cancer cells according to their receptor profiles, the role of ER remains controversial. A plausible explanation could be due to the uneven expressions of different membrane-related ERs in laryngeal cancer cells [50].

ERα and ERβ exhibit differential expression patterns even in the same HNC type and may exert various effects. For instance, ERα and ERβ may play different functions in the tumor growth and progression of the medullary thyroid carcinoma (MTC) [51]. Similarly, another study suggests that most cases of adenoid cystic carcinoma cases are positive for the expression of ERα and the five-year overall survival rate is significantly better in these cases relative to those with ERβ-positive expression [40]. Furthermore, the differential expression patterns of ERα and ERβ may induce opposite proliferative effects on the same type of HNC. For instance, the expression of ERα is positive for the growth of papillary thyroid cancer (PTC) cells due to autophagy [47], whereas ERβ exerts an inhibitory effect [52]. In thyroid carcinoma, ERs promote proliferation.

Based on recent empirical evidence, ERs including ERα and ERβ, exert an anti-apoptotic effect in some HNC types [31, 47-49]. In particular, in papillary thyroid cancer, ERα induces autophagy, which is a pro-survival catabolic phase owing to the stimulation of reactive oxygen species and extracellular signal-regulated kinases, wherein the
through different molecular mechanisms. Previous studies show that membrane-bound ERs mediate growth-promoting effects through classical genomic and non-genomic pathways, which are linked to the tyrosine kinase signaling cascades, including transduction through MAPK and PI3K [53]. Another study demonstrates that 17beta-estradiol is an effective mitogen for benign and malignant thyroid tumor cells, as it can bind to the nuclear ERs, thereby promoting growth by activating the MAPK pathway [54]. In addition, the ligand activation for GPR30 signaling, coupled with the upregulation of specific GPER genes, is involved in the proliferation of tumor cells, which implies that GPER can contribute to the tumorigenesis process [55, 56]. Taken together, ERα and ERβ modulate the estrogen signaling at the genomic level, while the third membrane-bound estrogen receptor GPR30 is involved in non-genomic transduction mechanisms and occupies an equally important position in the development of HNC.

Effects of AR on the biological behavior of HNC

AR shows positive expression in HNCs, including oropharyngeal squamous cell carcinoma and salivary gland tumors. In a previous study, all six cases of salivary duct carcinoma and 14 cases of carcinoma ex pleomorphic adenoma (a subset of salivary gland carcinoma) showed strong nuclear immune reactivity for AR. Moreover, the uniform expression of AR in malignant salivary gland carcinoma has been demonstrated [62-66]. In another study, AR expression was detected in tumor samples from oropharyngeal squamous cell carcinoma (OPSCC) patients. The results indicated that 16% (31/199) of the tumors were positive for AR expression, of which 61% (19/31) exhibited a strong expression [67]. Tarakji et al. reported AR expression in 50% of the cases of pleomorphic salivary adenoma by immunohistochemical nuclear staining [68]. Additionally, the high expression of AR is associated with oncogenesis. Wu et al. have investigated the oncogenic role of AR in oral squamous cell carcinoma (OSCC) and reported a high level of expression of AR in premalignant and malignant lesions relative to the normal mucosal tissues. They examined the clinical specimens and observed that OSCC cells expressed functional AR which promoted their growth [69]. However, a few tumors show detectably lower rates [67, 70, 71] of 16% to 26% AR-positive expression. Despite the differential rates of AR expression, notably, the risk factors for malignant tumors are indispensable and deserve greater research attention. The potential functional roles of AR in HNC are listed in Table 2.

Higher expression of AR contributes to the proliferation of cells in different HNC types, including laryngeal carcinoma and juvenile nasopharyngeal fibroma. For instance, stimulation of AR by DHT in OSCC cells causes an increase in cyclin D1 expression, resulting in enhanced cell growth [69]. Moreover, AR exerts a growth-promoting effect on cells in the larynx cancer [72, 73]. In juvenile
nasopharyngeal fibroma, the expression of AR is higher in tumor fibroblasts relative to the genital cells. Consequently, the growth rate of tumor fibroblasts increases due to the action of androgen, while that of the tumor cells is suppressed upon the addition of anti-androgen drugs [74]. However, there is no definitive description of the mechanism underlying AR involvement in the proliferation of HNC, and little is known about how androgens impact proliferation upon binding to AR.

| HNC Type                  | Expression | Prognosis | Function                  | Mechanism                  | Ref. |
|---------------------------|------------|-----------|---------------------------|----------------------------|------|
| Oral carcinoma            | Upregulation | NA        | Promote proliferation     | Upregulate cyclin D1 level and promote cell growth | [69] |
| Juvenile nasopharyngeal fibroma | Upregulation | NA        | Promote proliferation NA   | NA                         | [74] |
| Laryngeal cancer          | Upregulation | NA        | Promote proliferation NA   | NA                         | [73] |
| Salivary duct cancer      | Upregulation | NA        | Increase invasion NA       | NA                         | [76] |
| Micro-papillary salivary duct cancer | Downregulation | NA      | Increase aggression NA     | NA                         | [76] |
| Laryngeal cancer          | Downregulation | Favorable | Increase invasion NA       | NA                         | [102]|
| Differentiated thyroid cancer | Upregulation | NA        | Increase aggression NA     | NA                         | [77] |

Abbreviations: NA, not available; Ref: reference.

Interestingly, ARs exert opposite effects on proliferation in some cancer types. Recently, Hickey et al. have demonstrated that AR activation exhibits antitumor activity in ER-positive breast cancer. They found that the activation of AR altered the genomic distribution of ER and its important co-activators, leading to the repression of ER-regulated cell cycle genes and upregulation of AR-regulated tumor suppressors, thereby inhibiting proliferation of cancer cells [75]. These opposing roles of AR may allow for the targeted development of new and better therapies for specific cancer types.

AR contributes to the migration of AR-positive OSCC cells [32]. DHT acts as an AR-ligand that promotes AR-positive cell migration of OSCC by enhancing the expression of phosphorylated EGFR and AKT. Furthermore, upon treatment of SCC9 cells (AR-positive OSCC cells) with bicalutamide (an AR inhibitor), migration rate and the phosphorylation of EGFR and AKT, reduce. AR plays an important role in OSCC cell migration by regulating the EGFR signaling transduction [32]. On the contrary, similar to ERs, ARs can also reduce invasion. The presence of an invasive micro-papillary component in salivary duct carcinoma that is AR-negative reportedly contributes to checking of the primary site; however, ordinary salivary duct carcinoma is positive for AR [76]. In a study on small differentiated thyroid cancers (DTC), T1 cases according to the TNM Staging System, 2006 with AR-positive tumors showed more aggression as compared to the AR-negative tumors [77]. Taking into account, the relatively scarce previous data from the literature, further studies are required to determine the aggressive role of AR expression in different types of HNCs.

**Clinical significance of ER and AR in HNC**

According to their various biology functions, ERs play pivotal roles in the clinical disease progression of various HNC types. Accumulating evidence suggests that ERs are associated with shorter survival duration [78]. On the one hand, higher ERα expression significantly influences survival [39]. On the other hand, ERβ positive expression suggests improved survival rates in patients with oropharyngeal cancer [79]. Notably, the relationship between ER expression and other factors exerts essential effects in some cancer types, as well as exhibits a great impact on the development of HNC. However, this influence depends on the type of cancer, along with the correlation between the factor and ER expression. Several studies confirm that ER is associated with prolactin receptor (PRLR) [39], epidermal growth factor receptor (EGFR) [61], and the apolipoprotein B mRNA-editing catalytic polypeptide 3 A (APOBEC3A, A3A) [80]. The EGFR and ERα cross-talks are associated with poor prognoses because of enhanced tumor invasion [61]. This implies that ER can interact with another factor, thereby influencing the development and progression of HNC. Considering all these findings based on previous studies, ER may serve as a novel predictor for HNC, particularly as a prognosticator or biomarker [55, 61].

The relationship between levels of AR and HNC clinical progression cannot be overlooked. In several cases, the role of AR in the progression of other cancer types is consistent with HNC, that is, favorable for tumor growth [69, 81]. Empirical studies report that AR is closely associated with pathological classification, clinical stage, and lymph node metastasis, all of which can promote the growth of laryngeal carcinoma cells [73]. Some reports emphasize that intraprostatic/tumor AR heterogeneity is associated with unfavorable clinical prognoses [82], while for laryngeal squamous cell carcinoma, no significant differences in the survival curves between the low and high expression groups [39] have been observed. Overall, the correlation between AR expression and prognosis in HNC has been rarely documented and warrants further examination.
Application of ER and AR in HNC therapy

Increasing evidence demonstrates that ER and AR are involved in tumor initiation and progression. As described in previous sections, the expressions of ER and AR are high in HNC, indicating that they both are potential targets for HNC treatment. Some cases are amenable to anti-estrogen or anti-androgen therapy and are listed in Table 3 and Table 4, respectively.

Table 3. Application of anti-estrogen therapy in HNC

| Receptor | ER level | HNC Type          | Treatment | Response                        | Outcome                          | Ref. |
|----------|----------|-------------------|-----------|---------------------------------|----------------------------------|------|
| ER       | Positive | Laryngeal cancer  | Tamoxifen | Suppress the growth of cells    | NA                               | [103]|
| ERβ      | Positive | Tongue cancer     | Fulvestrant| Promote apoptosis                | NA                               | [41] |
| ER       | Positive | Salivary gland cancer | Tamoxifen/tore-mifene | Negative ER status after therapy | Long-term stability of disease | [84] |

Abbreviations: NA, not available; Ref: reference.

Given the impact of ER, HNC treatment benefits from the advantageous effects of anti-estrogen drugs. Studies indicate growth inhibition of ER-positive OSCC cells upon treatment with an ER antagonist, tamoxifen. ER promotes the growth of OSCC cells, while tamoxifen suppresses cell growth [83]. Nonetheless, the mechanisms through which these anti-estrogen agents exert anti-proliferative effects on laryngeal carcinoma cell lines remain unclear. However, the anti-estrogen agents prevent both translocation and nuclear binding of the receptor, thereby blocking ER, resulting in the inhibition of transcriptional activation of estrogen-responsive genes; they also possess potential disease-stabilizing effects in other cancer types [41, 84]. Hence, we speculate that ER-positive patients may benefit from anti-estrogen treatment owing to the blockade of E2 and ER-related signaling cascades. This may underlie the effects of anti-estrogen treatment in HNC.

Furthermore, ER is associated with unfavorable outcomes after chemoradiation in patients with HNC. Tamoxifen is favorable for overcoming resistance to cisplatin in HNC-squamous cell carcinoma cell lines by inducing G1 arrest and sensitizing the cells to cisplatin-induced apoptosis [85]. In vitro studies show that enhanced expression of human submaxillary gland androgen regulatory protein 3A (SMR3A) is accompanied by an upregulation in estrogen receptor 2 (ESR2) level after fractionated irradiation. ESR2-dependent regulation of SMR3A is supported by estradiol (E2) stimulation of SMR3A, and the co-treatment of estradiol (E2) with tamoxifen or fulvestrant, correspondingly, attenuate the regulation of SMR3A by ESR2. Both drugs significantly sensitize the HNC tumor cells to graded irradiation and accelerate apoptosis as evidenced by the results of the colony formation assay (CFA). These data suggest that ESR2 plays an important role in radioresistance [86]. In thyroid cancer, the estrogen-related receptor γ (ERRγ, a nuclear receptor with high sequence identity to ERs) inverse agonist contributes to enhanced sensitivity towards radioiodine therapy, suggesting that it may be beneficial in restoring the unresponsiveness of poorly differentiated thyroid cancer cells to radioiodine therapy [87]. On the contrary, ERα-positive oropharyngeal squamous carcinoma (OPSC) patients who underwent radiotherapy, show better overall, disease-free, progression-free, and relapse-free survival as compared to ERα-negative patients, suggesting that ERα may serve as a potential therapeutic target for OPSC [42]. Taken together, the role of ER in HNC chemoradiation therapy remains controversial and needs further validation.

Given the high expression of AR in most HNC cases, patients undergo treatment through androgen deprivation therapy (ADT), using bicalutamide (an androgen receptor antagonist with a non-steroidal structure) [18], abiraterone [88], and flutamide [89]. As first-line therapy for certain tumors, like the AR-positive salivary gland cancer [90], many patients benefit from ADT as it yields a higher response rate and better prognosis. Remarkably, 17 AR-positive salivary gland cancer patients who received ADT showed a 64.7% overall response rate, of which three showed a complete remission [91]. Patients treated with first-line ADT exhibited a higher response rate of 45% (9/20) as compared with those who received first-line chemotherapy (14% (2/14)) [90]. Additionally, relative to conventional chemotherapy, ADT has equivalent efficacy and less toxicity for unresectable locally advanced salivary gland carcinoma (SGC) [17]. However, the emergence of ADT resistance has reduced its efficiency [92]. The mechanisms underlying ADT resistance are linked to the low expression of androgen synthesis enzyme-encoding gene (SRD5A1) and low activity of the AR pathway. Thus, SRD5A1 may be a promising factor for enhancing responses to ADT in recurrent/metastatic SDC [92]. Moreover, the benefits of ADT in HNC patients may depend on the level of AR expression.
Studies show that the combination of chemotherapy or radiotherapy with ADT is more effective for HNC treatment. In a case report, the ADT plus radiation regime was used to definitively treat androgen receptor-positive SDC. The patient showed a good clinical outcome with no clinical evidence of disease after 24 months post-treatment completion [93]. In addition, AR positively correlates with overall survival in patients undergoing radiotherapy and chemotherapy after surgery for head and neck squamous cell carcinoma [94]. Reports show that AR expression is an independent prognostic factor for overall survival and metastases-free survival [94], however, the relationship between AR expression and chemoradiation is ambiguous. In the future, clinical trials are expected to address whether combined androgen blockade is better than chemotherapy or radiotherapy alone as a first-line treatment for metastatic cancers, along with its correlation with AR.

Conclusions and perspectives

This review summarized the potential roles of ER and AR in the progression of HNC. Based on the findings from several studies, further investigations are required to evaluate the functional roles and mechanisms underlying ER and AR involvement in the development of HNC and the putative benefits by alleviating negative effects on tumor growth and progression using antagonists of ER or AR. Differential levels of ER and AR elicit controversial effects in HNC progression, indicating a complexity in their status and roles, which requires further confirmation in certain cancer types.

FOXA1 and fatty acid synthase (FASN) may be associated with ADT resistance in prostate cancer [37, 95-99]. Similarly, FOXA1 and FASN are also present in patients with AR-positive salivary gland cancer [100], and therefore, may be also associated with other HNC types. Targeting ERα36 can reduce the detrimental effects of E2 in laryngeal cancer, suggesting the importance of the identification of novel drugs that specifically target the ERα36 [31]. Overall, all findings indicate the importance of anti-estrogen and anti-androgen therapies or the production of novel drugs targeting AR and ER in HNC.

Going forward, the possible effects of ER and AR, such as their involvement in oncogenesis and mediating cellular proliferation, make them prime candidates of novel and potential biomarkers or/and targets for cancer diagnosis and treatment. Given that the levels of expression of AR or ER are regulated by their upstream signaling pathways or transcription factors, for instance, tamoxifen interrupts MAPK and PI3K signaling cascades to reduce E2-induced proliferation by decreasing ER expression [101], targeting the upstream pathways or transcription factors of ER and AR maybe a novel approach for the treatment of HNC.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 82073101, 81872210, 81802948), the Research Funds for China Central Government-guided Development of Local Science and Technology (No. 2020-165-19), The Excellent talent science and technology innovation project of Shanxi Province (No. 201805D211007), Shanxi Province Scientific and Technological Achievements Transformation Guidance Foundation (No. 201804D131043), Shanxi Province Science Foundation for Excellent Young Scholars (No. 201901D211486), Shenzhen Key Laboratory Foundation (ZDSYS20200811143757022), Youth Fund of Health Commission of Shanxi Province (No. 2014083), Research Project of Health Commission of Shanxi Province (No. 2020039), Shanxi Province Science Foundation for Youths (No. 201601D021142), Research Project Supported by Shanxi Scholarship Council of China (No. 2020165), Fund for the Scientific Activities of Selected Return Overseas Professionals in Shanxi Province (No. 20200034).

Author Contributions

YYW, WG and SXW conceived the study. CHQ, YL, and HMZ wrote the first version of the manuscript. CHQ, HMZ and ZZ organized the figures. CHQ, YL, HMZ, WX, SXW, YYW, and WG revised the manuscript. All of the authors approved the final version of the manuscript.

Table 4. Application of anti-androgen therapy in HNC

| HNC Types                     | AR level | Treatment                                      | Response                        | Outcome          | Ref.  |
|-------------------------------|----------|-----------------------------------------------|---------------------------------|------------------|-------|
| Salivary gland cancer         | Positive | Bicalutamide and leuprrolin acetate           | Clinical benefit rate (75%)     | Favorable prognosis | [17]  |
| Salivary duct carcinoma       | Positive | Bicalutamide/combination with Goserein (LHRH analog) | Stable disease for 32% patients and 50% patients with clinical benefit | Favorable prognosis | [18]  |
| Salivary duct carcinoma       | Positive | Bicalutamide with external beam radiotherapy  | NA                              | Favorable prognosis | [93]  |
| Parotid gland adenocarcinoma  | Positive | Bicalutamide and Triptorelin (LHRH analog)    | A complete remission            | Favorable prognosis | [104] |
| Salivary gland cancer         | Positive | Cyproterone acetate and triptorelin           | Overall response rate 64.7%     | Favorable prognosis | [91]  |
| Salivary Duct Carcinoma       | Positive | Leuproside and bicalutamide                   | Good partial response after 3 and 6 months | Favorable prognosis | [105] |

Abbreviations: NA, not available; Ref: reference; LHRH: luteinizing hormone-releasing hormone.
Competing Interests

The authors have declared that no competing interest exists.

References

1. Patterson RH, Fischman VC, Wasserman I, et al. Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery. Otolaryngol Head Neck Surg. 2020; 162(3): 296-303.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7-30.

3. Holt J, Walter V, Yin X, et al. Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021; 27(3): 831-842.

4. Talani C, Mäkitie A, Beran M, Holmberg E, Laurell G, Farnebo L. Early mortality after diagnosis of cancer of the head and neck - A population-based nationwide study. PLoS One. 2019; 14(10): e0223154.

5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7-34.

6. Qi H, Chen W, Zhang C, et al. Epidemiological Analysis of 1234 Cases of Laryngeal Cancer in Shanxi Province, China. Cancer Control. 2021; 28(3): 304(12): 1124-1135.

7. Rettig EM, D’Souza G. Epidemiology of head and neck cancer. Surg Clin North Am. 2018; 98(4): 841-853.

8. Yang DL, Shi Y, Tang YM, et al. Effect of HPV Infection on the Occurrence and Development of Laryngeal Cancer: A Review. J Cancer. 2019; 10(19): 4455-4462.

9. Cohen N, Fedewa S, Chen AY. Epidemiology and Demographics of the Head and Neck Cancer Population. Oral Maxillofac Surg Clin North Am. 2019; 31(4): 381-395.

10. Vučičević Boras V, Fučić A, Baranović S, et al. Environmental and behavioural head and neck cancer risk factors. Cent Eur J Public Health. 2019; 27(2): 106-109.

11. Petit C, Lucas B, Pignon JP, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021; 22(5): 727-736.

12. Weppler S, Quon H, Schinkel C, Yarschenko A, Barbera L, Harjai N, et al. Patient-Reported Outcomes-Guided Adaptive Radiation Therapy for Head and Neck Cancer. Front Oncol. 2021; 11: 759724.

13. Brook I. Late side effects of radiation treatment for head and neck cancer. Radiat Oncol J. 2020; 38: 84-92.

14. Schlichting JA, Pagedar NA, Chioreso C, Lynch CF, Charlton ME. Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis. Cancer Causes Control. 2019; 30(7): 721-732.

15. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction network meta-analysis. Lancet Oncol. 2021; 22(5): 727-736.

16. Niwa T, Takanobu J, Suzuki K, Sato Y, Yamaguchi Y, Hayashi SI. Critical role of estrogen receptor on hormone receptors in prostate cancer patients. J Natl Cancer Inst. 2019; 111: 933-42.

17. Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin andゲルシンマム in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis. Biostat. 2021; 10(10): 1011.

18. Fei MJ, Xu YN, Wang JD. The expression and clinical progression of estrogen receptor-positive prostate cancer. Cancer Sci. 2019; 19(1): 1094.

19. Liao SD, Su CY, Chiang HC, Huang CC, Chen CM, Chien CY. Estrogen receptor overexpression in malignant minor salivary gland tumors of the sinonasal tract. Otolaryngol Head Neck Surg. 2009; 141(1): 108-113.

20. Shatalova EG, Klein-Szanto AJ, Devarajan K, Cukierman E, Clapper ML. Reactive oxygen species and extracellular signal regulated kinases. J Clin Oncol. 2015; 33(2-3): 413-27.

21. Kamata YU, Sumida T, Murase R, Nakano H, Yamada T, Mori Y. Blockade of Androgen-induced Malignant Phenotypes by Flutamide Administration in Human Salivary Duct Carcinoma Cells. Anticancer Res. 2016; 36(11): 6071-6075.

22. Koenigs MB, Lefranc-Torres A, Bonilla-Velez J, Patel KB, Hayes DN, Glomski K, et al. Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy. J Natl Cancer Inst. 2019; 111: 933-42.

23. Liang L, Williams MD, Bell D. Expression of PTEN, Androgen Receptor, and Endocrine 5α-reductase 2 in prostate cancer: a clinicopathological analysis on 822 cases. Prostate. 2008; 68(10): 1054-1064.

24. Vannucchi G, De Leo S, Perrino M, et al. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. J Clin Endocrinol Metab. 2015; 100(3): E561-71.

25. Ishida H, Wada K, Masuda T, et al. Critical role of estrogen receptor on anoxia and invasion of squamous cell carcinoma. Cancer Sci. 2007; 98(5): 636-43.

https://www.jcancer.org
50. Schwartz N, Verma A, Muktipaty C, Bivens C, Schwartz Z, Boyan BD. Androgens as a new class of therapeutic agents for medullary thyroid carcinoma. Endocrinology. 2018; 159(1): 19-30.

51. Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, et al. Preclinical study of anandrostenedione as a new therapeutic agent for androgen receptor-positive prostate cancer. Cancer Res. 2020; 80(20): 5828-5839.

52. Huang Y, Dong W, Li J, Zhang H, Shan Z, Teng W. Differential expression of estrogen receptor subtypes in papillary thyroid carcinoma. BMC Cancer. 2014; 14: 383.

53. Sumida T, Ishikawa A, Mori Y. Stimulation of the Estrogen Axis Induces Development of Papillary Thyroid Carcinoma. Semin Cancer Biol. 2020; 73(20): 58-75.

54. Verma A, Schwartz N, Cohen DJ, et al. Loss of Estrogen Receptors is Associated with Increased Tumor Aggression in Laryngeal Squamous Cell Carcinoma. Cancer Res. 2020; 80(1): 422-431.

55. Mitani Y, Lin SH, Pytynia KB, Ferrarotto R, El-Naggar AK. Reciprocal expression of estrogen receptor alpha and beta in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J Endocrinol. 2007; 195(2): 255-63.

56. Chen Z, Xuan Q, Zhao D, Wu S, Yin J, Pan H. Roles of G protein-coupled receptor 30 in the effects of genistein on apoptosis and cell cycle in human thyroid squamous cells SW579. Wei Sheng Yan Jiu. 2020; 49(5): 780-784.

57. Verma A, Schwartz N, Cohen DJ, et al. Loss of Estrogen Receptors is Associated with Increased Tumor Aggression in Laryngeal Squamous Cell Carcinoma. Cancer Res. 2020; 80(1): 422-431.

58. Goulioumis AK, Fue X, Varakis J, Repanti M, Goumas P, Papadaki H. Estrogen receptor-beta expression in human laryngeal carcinoma: correlation with the expression of epithelial-mesenchymal transition specific biomarkers. Oncol Rep. 2009; 22: 1063-1068.

59. Sumida T, Ishikawa A, Mori Y. Stimulation of the Estrogen Axis Induces Development of Papillary Thyroid Carcinoma. Semin Cancer Biol. 2020; 73(20): 58-75.

60. Wen DS, Wu JZ, Fu SM, Liu B, Li XX, Dong JJ. Effects of 17 beta-estradiol on the adhesion, invasion and motility potential of salivary mucoepidermoid carcinoma Mc3 cells. Zhonghua Kou Qiang Yi Xue Za Zhi. 2005; 40(5): 390-3.

61. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res. 2009; 15(21): 6529-40.

62. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Oral Pathol Oral Cir Bucal. 2011; 16(3): e330-4.

63. Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, et al. Preclinical study of anandrostenedione as a new therapeutic agent for androgen receptor-positive prostate cancer. Cancer Res. 2020; 80(20): 5828-5839.

64. Schvartsman G, Bell D, Rubin ML, et al. The tumor immune contexture and Autonomous Glucocorticoid and Androgen Receptor Activation in Human Salivary Gland Adenoid Cystic Carcinoma: report of two cases. J Cancer Res Clin Oncol. 2008; 134(10): 1151-3.

65. Tanakasol M, Soltanian J, Rudnicka J, Mashanyarde D, Johnson N, Câken J. Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin-induced-apoptosis: role of TGF-beta1. Carcinogenesis. 2002; 23: 1569-75.

66. Rong C, EFRC M, Hess J. Estrogen Receptor Signaling in Radiotherapy: From Molecular Mechanisms to Clinical Studies. Int J Mol Sci. 2018; 19(3): 713.

67. Kim J, Hwang H, Yoon H, Lee JE, Oh JM, An H, et al. An orally available inhibitor of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer. Eur J Med Chem. 2020; 205: 112501.

68. Locati LD, Perrone F, Cortelazzi B, Imbimbo B, Bossi P, Poterap P, et al. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther. 2014; 15(6): 678-682.

69. Jaspers HC, Verhaegh GW, van Engen-van Grunsven IA, van Strijp D, van der Voort T, Kruizinga M, et al. Effect of androgen receptor status on the outcome of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011; 29: 437-44.

70. Viscuse PV, Price KA, Garcia J, Schmehl-Wissamay DJ, Chintakuntlawar AV. First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study. Front Oncol. 2019; 9: 701.

71. Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2016; 38(5): 724-31.

72. van Boxtel W, Verhaegh GW, van Engen-van Grunsven IA, van Strijp D, Jaspers HC, Schoffelen R, Mattijssen V, Slootweg PJ, van der Voort T, Kruizinga M, et al. Effect of androgen receptor status on the outcome of androgen deprivation therapy for prostate cancer. Cancer Biol Ther. 2014; 15(6): 678-682.

73. Wang JQ, Dong Z, Zhu JG, Bu GX, Guo XF. Androgen receptors in laryngeal carcinoma and their clinical significance. Chin Med J (Engl). 1991; 104(12): 992-4.

74. Hagen R, Romalo G, Schwab B, Hoppe F, Schweikert HU. Juvenile nasopharyngeal fibroma: androgen receptors and their significance for tumor growth. Laryngoscope. 1994; 104(9): 1125-9.

75. Hickey TE, Seth LA, Chia KM, Laven-Law G, Milioni HL, Roden D, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021; 27: 310-20.

76. Yamamoto H, Uryu H, Segawa Y, Tsuneyoshi M. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland. Pathol Int. 2008; 58(8): 322-6.

77. Magri F, Capelli V, Rotondi M, et al. Expression of estrogen and progesterone receptors in head and neck cancer. Int J Oncol. 2007; 30(1): 155-160.

78. Gric K, Opacic IL, Sitic S, Milikovic Perisina M, Suto P, Sarcevic B. The prognostic significance of estrogen receptor β in head and neck squamous cell carcinoma. Oncol Lett. 2016; 12(5): 3861-3865.

79. Kano M, Kondo S, Wakisaka N, et al. Expression of estrogen receptor alpha is associated with pathogenesis and prognosis of human papillomavirus-positive oropharyngeal cancer. Int J Cancer. 2019; 145(6): 1547-1557.

80. Li TH, Zhao H, Peng Y, Belakofik J, Brooks JD, Sun Z. A promoting role of androgen receptor in aggressive and sensitive -insensitive prostate cancer cells. Nucleic Acids Res. 2007; 35: 2767-76.

81. Grivas PD, Robires DM, Hussain M. Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. Crit Rev Oncol Hematol. 2013; 85(1): 82-93.

82. Chang YL, Hsu YK, Wu TF, et al. Regulation of estrogen receptor α function in oral squamous cell carcinoma cells by FAK signaling. Endocr Relat Cancer. 2014; 21(4): 555-66.

83. Elkin AD, Jacobs CD. Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. J Cancer Res Clin Oncol. 2008; 134(10): 1151-3.
radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression. EBioMedicine. 2019; 40: 504-16.
96. Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell. 2021; 12: 29-38.
97. Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019; 116: 631-40.
98. Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, et al. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. Mol Cancerog. 2016; 35: 2278-90.
99. Kregel S, Bagamasbad P, He S, LaPensee E, Raji Y, Brogley M, et al. Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element. Nucleic Acids Res. 2020; 48: 4741-55.
100. Dalin MG, Watson PA, Ho AL, Morris LG. Androgen Receptor Signaling in Salivary Gland Cancer. Cancers (Basel). 2017; 9(2): 17.
101. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol. 2010; 36(5): 1067-80.
102. Atef A, El-Rashidy MA, Elzayat S, Kabel AM. The prognostic value of sex hormone receptors expression in laryngeal carcinoma. Tissue Cell. 2019; 57: 84-89.
103. Robbins KT, Vu TP, Diaz A, Varki NM. Growth effects of tamoxifen and estradiol on laryngeal carcinoma cell lines. Arch Otolaryngol Head Neck Surg. 1994; 120(11): 1261-1266.
104. Locati LD, Quattromini P, Bossi P, Marchianò AV, Cantù G, Licitra L. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol. 2003; 14(8): 1327-8.
105. Jeong I, Moyers J, Thung I, Thinn MM. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma. Am J Case Rep. 2020; 21: e925181.